Abstract: Provided herein are various regimens for treating acute myeloid leukemia (AML) in subjects (e.g, patients) who have undergone one or more prior anti-AML therapies involving venetoclax, and have shown disease progression after the one or more prior therapies. The treatment regimens disclosed herein involve alvocidib, either as a monotherapy, or in combination with cytarabine or a hypomethylating agent, such as decitabine or azacitidine. The treatment regimens disclosed herein do not involve combination therapy of alvocidib with venetoclax.

Abstract: Provided herein are various regimens for treating acute myeloid leukemia (AML) in subjects (e.g, patients) who have undergone one or more prior anti-AML therapies involving venetoclax, and have shown disease progression after the one or more prior therapies. The treatment regimens disclosed herein involve alvocidib, either as a monotherapy, or in combination with cytarabine or a hypomethylating agent, such as decitabine or azacitidine. The treatment regimens disclosed herein do not involve combination therapy of alvocidib with venetoclax.

Abstract: Provided herein are methods for monitoring the development of tumor lysis syndrome (TLS) in subjects being treated for cancer with alvocidib, and methods for treating cancer using such monitoring methods. Methods for monitoring a subject for TLS can comprise performing a laboratory TLS panel on the subject about three to about four hours after the end of an alvocidib administration. Methods for treating cancer comprise administering an effective amount of alvocidib to a subject, monitoring the subject being treated with alvocidib for TLS, and administering to the subject an effective amount of one or more TLS therapies if the subject has an elevated serum potassium level or an abnormal laboratory TLS panel.

Abstract: The present invention relates to novel variants of human glial cell-derived neurotrophic factor (GDNF) and methods for their use.

Abstract: The present invention relates to therapeutic uses of soluble alpha-Klotho.

Abstract: The present invention relates to novel variants of human glial cell-derived neurotrophic factor (GDNF) and methods for their use.

Abstract: Systems and methods for delivering health information by combining print and audio information are provided. The systems utilize prerecorded audio systems, with or without recordable audio systems, in conjunction with print material to deliver individualized, patient-specific health information and/or instructions to a patient or caregiver. The method allows patients to collect and retain personalized, voice-recorded health material in the same location as printed and prerecorded health information. The present invention overcomes the limitations of the prior art by to provide to a patient or caregiver the ability to store, record, and deliver audio voice-recorded material along with print material in order to deliver individualized health information.

Abstract: The present invention relates to therapeutic uses of soluble alpha-Klotho.

Abstract: Systems and methods for delivering health information by combining print and audio information are provided. The systems utilize prerecorded audio systems, with or without recordable audio systems, in conjunction with print material to deliver individualized, patient-specific health information and/or instructions to a patient or caregiver. The method allows patients to collect and retain personalized, voice-recorded health material in the same location as printed and prerecorded health information.

Abstract: Anti-myostatin antibodies are identified that are characterized as having high affinity and may be chimeric, humanized or fully human antibodies, immunoconjugates of the antibodies or antigen-binding fragments thereof. The antibodies of the invention are useful for increasing muscle mass, increasing bond density, or for the treatment of various disorders in mammalian and avian species, X17251.

Abstract: A neutralizing epitope is identified within amino acids 40-64 of the mature form of human myostatin. Antibodies that bind this epitope with high affinity preferentially bind GDF-8 over GDF-11 and may be chimeric, humanized or fully human antibodies, immunoconjugates of the antibodies or antigen-binding fragments thereof. The antibodies of the invention are useful for increasing muscle mass, increasing hone density, or for the treatment of various disorders in mammalian and avian species.

Abstract: A neutralizing epitope is identified within amino acids 40-64 of the mature form of human myostatin. Antibodies that bind this epitope with high affinity preferentially bind GDF-8 over GDF-11 and may he chimeric, humanized or fully human antibodies, immunoconjugates of the antibodies or antigen-binding fragments thereof. The antibodies of the invention are useful for increasing muscle mass, increasing hone density, or for the treatment of various disorders in mammalian and avian species.

Abstract: Anti-myostatin antibodies are identified that are characterized as having high affinity and may be chimeric, humanized or fully human antibodies, immunoconjugates of the antibodies or antigen-binding fragments thereof. The antibodies of the invention are useful for increasing muscle mass, increasing bone density, or for the treatment of various disorders in mammalian and avian species.

Abstract: A neutralizing epitope is identified within amino acids 40-64 of the mature form of human myostatin. Antibodies that bind this epitope with high affinity preferentially bind GDF-8 over GDF-11 and may be chimeric, humanized or fully human antibodies, immunoconjugates of the antibodies or antigen-binding fragments thereof. The antibodies of the invention are useful for increasing muscle mass, increasing bone density, or for the treatment of various disorders in mammalian and avian species.

Abstract: Anti-myostatin antibodies are identified that are characterized as having high affinity and may be chimeric, humanized or fully human antibodies, immunoconjugates of the antibodies or antigen-binding fragments thereof. The antibodies of the invention are useful for increasing muscle mass, increasing bone density, or for the treatment of various disorders in mammalian and avian species.

Abstract: Anti-myostatin antibodies are identified that are characterized as having high affinity and may be chimeric, humanized or fully human antibodies, immunoconjugates of the antibodies or antigen-binding fragments thereof. The antibodies of the invention are useful for increasing muscle mass, increasing bone density, or for the treatment of various disorders in mammalian and avian species.

Abstract: A neutralizing epitope is identified within amino acids 40-64 of the mature form of human myostatin. Antibodies that bind this epitope with high affinity preferentially bind GDF-8 over GDF-11 and may be chimeric, humanized or fully human antibodies, immunoconjugates of the antibodies or antigen-binding fragments thereof. The antibodies of the invention are useful for increasing muscle mass, increasing bone density, or for the treatment of various disorders in mammalian and avian species.

Abstract: The present invention relates to a method for dosing and dispensing a laundry detergent, preferably a liquid laundry detergent, into a washing machine comprising the steps of: i) measuring a dose of laundry detergent into a dosing and dispensing device (10) comprising a hollow cavity defined by a base (11) and side-walls (12), wherein the base (11) and/or side walls (12) are at least partly covered by a sleeve (20), and wherein the sleeve (20) comprises a film of material comprising printed indicia (21) thereupon, wherein the printed indicia (21) are resistant to removal from the film when the dosing and dispensing device (10) is exposed to wash conditions inside a washing machine; ii) placing both the laundry and the dosing and dispensing device containing laundry detergent into a washing machine, and running the washing machine on a selected cleaning cycle; and iii) subsequently reusing the dosing and dispensing device (10) for steps i) and ii).

Abstract: Compositions and methods for the therapy and diagnosis of cancer, such as colon cancer, are disclosed. Compositions may comprise one or more colon tumor proteins, immunogenic portions thereof, or polynucleotides that encode such portions. Alternatively, a therapeutic composition may comprise an antigen presenting cell that expresses a colon tumor protein, or a T cell that is specific for cells expressing such a protein. Such compositions may be used, for example, for the prevention and treatment of diseases such as colon cancer. Diagnostic methods based on detecting a colon tumor protein, or mRNA encoding such a protein, in a sample are also provided.

Abstract: A system is described using a fuel quality sensor for controlling various aspects of engine operation. In particular, an acoustic wave sensor is utilized to measure viscosity and density of gasoline fuels. This measurement is utilized to predict engine combustion quality during an engine start. Based on the prediction, the method adjusts engine operating parameters (such as fuel injection amount and ignition timing) to achieve improved vehicle driveability and engine combustion.